RE:of course, we only sold 30% of the ==>voucher<==Spent $100's of M's on getting Ryplazim to this point and selling it for $5M. And there is an option to buy later in case the PDUFA date gets pushed back. This mgmt is horrible being so overpaid and then signing a pathetic deal for crumbs. Why did they decide to continue with Ryplazim years ago? Why didn't they focus on small molecule doing a multiple ascending dosage study 4 years ago? It's just a total bungling of poor priorities and delays. This is on its deathbed and market will slowly crush it.